Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure. Results From COMET

Journal of the American College of Cardiology

Volumn 49, Issue 9, 2007, Pages 963-971

  Remme, Willem J ^a   Torp Pedersen, Christian ^b   Cleland, John G F ^c   Poole Wilson, Philip A ^d   Metra, Marco ^e   Komajda, Michel ^f   Swedberg, Karl ^g   Di Lenarda, Andrea ^h   Spark, Phillip ⁱ   Scherhag, Armin ^j   Moullet, Christine ^j   Lukas, Mary Ann ^k  

^a Sticares Cardiovascular Research Foundation   (Netherlands)

^b BISPEBJERG HOSPITAL   (Denmark)

^c UNIVERSITY OF HULL   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e UNIVERSITY OF BRESCIA   (Italy)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF TRIESTE   (Italy)

ⁱ Nottingham Clinical Research Group   (United Kingdom)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

^k GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; METOPROLOL;

ADRENERGIC RECEPTOR BLOCKING; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE;

ADRENERGIC BETA-ANTAGONISTS; ANGINA, UNSTABLE; CARBAZOLES; CEREBROVASCULAR ACCIDENT; DEATH, SUDDEN, CARDIAC; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPANOLAMINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33847403173     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.10.059     Document Type: Article

References (33)

1. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 1349-1355
2. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 353 (1999) 9-13
3. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in congestive heart failure (MERIT-HF). Lancet 353 (1999) 2001-2007
4. Packer M., Coats A.J.S., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
5. Doughty R.N., Whalley G.A., Gamble G., et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 29 (1997) 1060-1066
6. Remme W.J., Riegger G., Hildebrandt P., et al., CARMEN Investigators. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The Carvedilol and Ace-inhibitor Remodelling Mild heart failure EvaluatioN trial (CARMEN)Cardiovasc Drugs Ther 18 (2004) 57-66
7. Poole-Wilson P.A., Swedberg K., Cleland J.G.F., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
8. Kindermann M., Maack C., Schaller S., et al. Carvedilol but not metoprolol reduces β-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation 109 (2004) 3182-3190
9. Billman G.E., Castillo L.C., Hensley J., Hohl C.M., and Altschud R.A. Beta 2-adrenergic receptor antagonists protect against ventricular fibrillation. In vivo and in vitro evidence for enhanced sensitivity to beta 2-adrenergic stimulation in animals susceptible to sudden death. Circulation 96 (1997) 1914-1922
10. Du X.J., Autelitano D., Dilley R.J., Wang B., Dart A.M., and Woodcock E.A. β2-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 101 (2000) 71-77
11. Sattar M.A., and Johns E.J. Alpha-1 adrenoceptor subtypes involved in mediating adrenergically induced antinatriuresis and antidiuresis in two kidney, one clip Goldblatt and deoxycorticosterone acetate-salt hypertensive rats. J Pharmcol Exp Ther 277 (1996) 245-252
12. Poole-Wilson P.A., Cleland J.G., Di Lenarda A., et al. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. Eur J Heart Fail 4 (2002) 321-329
13. Di Lenarda A., Sabbadini G., Salvatore L., et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle-Disease Study Group. J Am Coll Cardiol 33 (1999) 1926-1934
14. Sanderson J.E., Chan S.K.W., Yip G., et al. Beta-blockade in heart failure. A comparison of carvedilol with metoprolol. J Am Coll Cardiol 34 (1999) 1522-1528
15. Metra M., Gibbini R., Nodari S., Boldi E., Modena M.G., and Dei Cas L. Differential effects of beta-blockers in patients with heart failure. A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 102 (2002) 546-551
16. Packer M., Antonopoulos G.V., Berlin J.A., Chittams J., Konstam M.A., and Udelson J.E. Comparative effects or carvedilol and metoprolol on left ventricular ejection fraction in heart failure: a meta-analysis. Am Heart J 141 (2001) 899-907
17. McMurray J., Kober I., Robertson M., et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction. Results of the carvedilol post-infarct survival control in left ventricular dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45 (2005) 525-530
18. Von zur Muhlen B., Millgard J., and Lind L. Divergent effects of different beta-blocking agents on endothelin-dependent vasodilatation in the human forearm. Blood Press 9 (2000) 287-292
19. Hryniewicz K., Androne A.S., Hudaihed A., and Katz S.D. Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure. Circulation 108 (2003) 971-976
20. Intengan H.D., and Schiffrin E.L. Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries. J Cardiovasc Pharmacol 35 (2000) 763-768
21. Matsuda Y., Akita H., Terashima M., Shiga N., Kanazawa K., and Yokoyama M. Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J 140 (2000) 753-759
22. Lopez B.L., Christopher T.A., Yue T.L., Ruffolo R., Feuerstein G.Z., and Ma X.L. Carvedilol, a new beta-adrenoceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Pharmacology 51 (1995) 165-173
23. Gao F., Chen J., Lopez B.L., et al. Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. Eur J Pharmacol 406 (2000) 109-116
24. Ma X.L., Yue T.L., Lopez B.L., et al. Carvedilol, a new beta-adrenoceptor blocker and free radical scavenger attenuates myocardial ischemia reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther 277 (1996) 128-136
25. Khandoudi N., Percevault-Albadine J., and Bril A. Comparative effects of carvedilol and metoprolol on cardiac ischemia-reperfusion injury. J Cardiovasc Pharmacol 32 (1998) 443-451
26. Oliveira P.J., Rolo A.P., Monteiro P., Goncalves L., Palmeira C.M., and Moreno A.J. Impact of carvedilol on the mitochondrial damage induced by hypoxanthine and xanthine oxidase-what role in myocardial ischemia and reperfusion?. Rev Port Cardiol 21 (2002) 1447-1455
27. Asanuma H., Minamino T., Sanada S., et al. Beta-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts. Circulation 109 (2004) 2773-2779
28. Romeo F., Li D., Shi M., and Mehta J.L. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res 45 (2000) 788-794
29. Rossig L., Haendeler J., Mallat Z., et al. Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol 36 (2000) 2081-2089
30. Chen J.W., Lin F.Y., Chen Y.H., Wu T., Chen Y.L., and Lin S.J. Carvedilol inhibits tumor necrosis factor-alpha-induced endothelial transcription factor activation, adhesion molecule expression and adhesiveness to human mononuclear cells. Arterioscler Thromb Vasc Biol 24 (2004) 2075-2081
31. Kurz T., Richardt D., Gorge B., et al. Differential effects of carvedilol on norepinephrine release in normoxic and ischemic heart. J Cardiovasc Pharmacol 36 (2000) 96-100
32. Metra M., Torp-Pedersen C., Swedberg K.S., et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 26 (2005) 2259-2268
33. Cleland J.G.F., Pennell D.J., Ray S.G., et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised, controlled trial. Lancet 362 (2003) 14-21